Latest news with #Endeavor
9 hours ago
- Business
Flight attendant says Delta put 'profits over safety' in Toronto plane crash
A flight attendant awarded for her heroism after the Delta Air Lines crash in Toronto earlier this year is now suing the company, alleging it cut corners on safety and knowingly put passengers at risk, CBC News has learned. In a 15-page complaint filed in U.S. federal court in Michigan this week, Vanessa Miles says she was badly injured in the incident and is seeking at least $75 million US in damages. The lawsuit claims Delta and its subsidiary, Endeavor Air, are liable for negligence after assigning an inexperienced pilot and failing to properly train the flight crew. The airlines have not responded to Miles's allegations and her claims have not been tested in court. The fiery landing on Feb. 17 saw the Bombardier CRJ-900 flip upside down and skid along the runway at Toronto's Pearson International Airport, sending at least 21 people to hospital. Flight 4819 — operated by Endeavor — had taken off from Minneapolis with 80 passengers and crew. Enlarge image (new window) Longtime flight attendant Vanessa Miles says in a $75-million US lawsuit that she was severely injured in the February crash of Delta Air Lines Flight 4819 in Toronto. Photo: Mike Morse Law Firm According to her lawsuit, the 67-year-old was employed as an Endeavor flight attendant at the time of the incident, but wasn't working that afternoon. Instead, she flew as a passenger to be in position for her next assignment — a practice in the industry commonly known as deadheading. Attorney blames 'somebody's negligence' Michael Morse, the owner of the law firm hired by the plaintiff said Miles is still an Endeavor employee, but has been unable to work while recovering from her injuries. Something went wrong here, Morse said in an interview. These things don't just happen without somebody's negligence. In the complaint, Miles recounts being rendered unconscious while hanging upside down from her seatbelt after the plane came to a stop on its roof. She regained consciousness and found herself soaked in jet fuel and surrounded by smoke, Miles's lawyer Madeline M. Sinkovich wrote. Miles, who lives in Detroit, was treated in a Toronto hospital and suffered multiple injuries, including to her knees and back, a broken left shoulder, plus post-traumatic stress disorder, according to her lawsuit. Defendants knowingly, willfully, and repeatedly place profits over safety, resulting in this catastrophic incident and Plaintiff's severe injuries, the complaint reads. Enlarge image (new window) The wreckage of a Delta Air Lines-operated CRJ900 aircraft lays on the runway after a plane crash at Toronto Pearson International Airport on Feb. 18. Photo: Reuters / Cole Burston Miles alleges the airlines displayed a disregard for passenger safety in pursuit of operational efficiency by assigning an inexperienced and inadequately trained pilot. What's more, she says Delta and Endeavor failed to properly maintain the plane's landing gear or establish adequate emergency response procedures. Miles was among the airline staff honoured earlier this year by the U.S. Association of Flight Attendants with an award for their heroism beyond the call of duty in the minutes following the crash. Miles and another off-duty flight attendant sprang into action, assisting [the cabin crew] in an effort to get everyone to safety, even while injured themselves, the association said. Companies deny claims Her lawsuit adds to a growing chorus of complaints filed in U.S. courts in connection with the Toronto incident. According to a CBC News review of court records, Canadian and U.S. passengers have filed at least 19 lawsuits against Delta and its Minnesota-based subsidiary. Plaintiffs claim that these injuries and losses are Delta's and Endeavor's fault, and not the fault of any other party, the companies' attorney Michael G. McQuillen wrote in a filing in May. Defendants deny these allegations. Delta spokesperson Morgan Durrant declined to comment on the case but said in an email that both flight crew members on Flight 4819 were qualified and [U.S. Federal Aviation Administration] certified for their positions. WATCH | Air safety investigators reveal initial findings: Canada's Transportation Safety Board (TSB) previously said the first officer — who completed her training 10 months before the crash — was operating the aircraft at the time, while the more experienced captain was seated next to her. Durrant said Delta and Endeavor are cooperating with the ongoing TSB investigation. When the TSB released its preliminary findings (new window) in March, it noted a high rate of descent in the flight's final seconds, as well as an unusual nose pitch. Still, the agency said it was too early to tell what caused the hard landing. The TSB's full report into the incident is expected to be released by the fall of 2026.
Miami Herald
5 days ago
- Science
- Miami Herald
NASA crew readies for ISS mission launch on Thursday
July 26 (UPI) -- An international crew of four is readying for Thursday's planned launch of a NASA mission to the International Space Station after arriving at the Kennedy Space Center in Florida. Astronauts Zena Cardman and Mike Fincke, Japanese Aerospace Exploration Agency specialist Kimiya Yui and Roscosmos cosmonaut Oleg Platonov will travel from Kennedy Space Center's Launch Complex 39A to the ISS while aboard the SpaceX Crew Dragon Endeavour. Cardman is the mission's leader. The crew landed at Space Florida's Launch and Landing Facility at 1:12 EDT after leaving from Houston on Saturday morning. "We are absolutely joyed to be here at Kennedy Space Center," Cardman said upon the crew's landing. "This is the first moment when it's really starting to feel real," she said. "This is the beginning of a week when things will feel progressively more and more real as we approach our launch." Mission pilot Fincke said the mission gives him another chance to fly aboard a spacecraft named Endeavour. "One of the last times I landed at the [Florida launch and landing facility] was on space shuttle Endeavour," Fincke told media. "Now we get to go on another endeavor - a Dragon Endeavour," he said. The Endeavour name honors the HMS Endeavour, which British Capt. James Cook used to explore and chart the South Pacific from 1768 to 1771. A SpaceX Falcon 9 rocket will deliver the Endeavor into low Earth orbit, which will make the Crew Dragon spacecraft the most flown among SpaceX's fleet. Thursday's launch is scheduled at 12:09 p.m. EDT and would enable the Endeavor to dock at the ISS on Aug. 2 if the launch occurs as planned. The four crew members will join Expedition 73, which already is at the ISS. An Expedition 74 crew is scheduled to replace the Expedition 73 crew while the Crew 11 team is at the ISS. Copyright 2025 UPI News Corporation. All Rights Reserved.
UPI
5 days ago
- Science
- UPI
NASA crew readies for ISS mission launch on Thursday
1 of 5 | NASA Crew 11 Commander Zena Cardman addresses media after arriving at the Kennedy Space Center in Florida on Saturday. Photo by Joe Marino/UPI | License Photo July 26 (UPI) -- An international crew of four is readying for Thursday's planned launch of a NASA mission to the International Space Station after arriving at the Kennedy Space Center in Florida. Astronauts Zena Cardman and Mike Fincke, Japanese Aerospace Exploration Agency specialist Kimiya Yui and Roscosmos cosmonaut Oleg Platonov will travel from Kennedy Space Center's Launch Complex 39A to the ISS while aboard the SpaceX Crew Dragon Endeavour. Cardman is the mission's leader. The crew landed at Space Florida's Launch and Landing Facility at 1:12 EDT after leaving from Houston on Saturday morning. "We are absolutely joyed to be here at Kennedy Space Center," Cardman said upon the crew's landing. "This is the first moment when it's really starting to feel real," she said. "This is the beginning of a week when things will feel progressively more and more real as we approach our launch." Mission pilot Fincke said the mission gives him another chance to fly aboard a spacecraft named Endeavour. "One of the last times I landed at the [Florida launch and landing facility] was on space shuttle Endeavour," Fincke told media. "Now we get to go on another endeavor - a Dragon Endeavour," he said. The Endeavour name honors the HMS Endeavour, which British Capt. James Cook used to explore and chart the South Pacific from 1768 to 1771. A SpaceX Falcon 9 rocket will deliver the Endeavor into low Earth orbit, which will make the Crew Dragon spacecraft the most flown among SpaceX's fleet. Thursday's launch is scheduled at 12:09 p.m. EDT and would enable the Endeavor to dock at the ISS on Aug. 2 if the launch occurs as planned. The four crew members will join Expedition 73, which already is at the ISS. An Expedition 74 crew is scheduled to replace the Expedition 73 crew while the Crew 11 team is at the ISS.
Otago Daily Times
7 days ago
- Entertainment
- Otago Daily Times
Canterbury board game creator scores big win
Carl de Visser and his board game Endeavor: Deep Sea, which recently won the Kennerspiel des Jahres award in Germany. PHOTO: OLIVIA JUDD A Cheviot man has gone global with his board game creation, taking out the highest honour in the world of tabletop gaming. Carl de Visser has won the 2025 Kennerspiel des Jahres— the world's most prestigious award in the strategy board game industry, for his cocreation Endeavor: Deep Sea. The award, presented annually in Berlin, Germany, recognises excellence in complex board game design. Carl and his co-creator Jarratt Gray spent a year and a half designing the under-the-sea themed board game, which builds on the foundations of an earlier game created by the pair in 2009, called Endeavor, which Carl says is more colonial themed. ''We basically re-did it from scratch with some of the same mechanics,'' says Carl. ''This one you're leading an ocean institute and you go out and explore the sea, you start on the surface and go deeper and deeper underwater.'' In the game, players build a team to form their institute gaining access to new actions and challenges as they explore five different ocean depths. Wining the award was a full circle moment for Carl, who has followed the Kennerspiel for years, and even makes an effort to purchase the winning game each year. The awards are paid attention to worldwide, and has many global entries, however to be eligible to enter the awards, your game has to be for sale in Germany. Endeavor: Deep Sea is played internationally, and Carl says is most popular in Germany and the United States. ''This kind of board game is taken a bit more seriously over in Germany— I arrived in Berlin and went to a pharmacy, and they had a board game section in the pharmacy.'' Carl says winning the award has seen a huge spike in sales for the game. Next, Carl and his co-creator Jarratt are working on an expansion to the game, called Endeavor Deep Sea: Uncharted Waters, which Carl hopes will be released by the end of next year. Carl's game is able to be purchased online.
Business Wire
16-07-2025
- Business
- Business Wire
Endeavor BioMedicines Receives Orphan Drug Designation from the U.S. Food and Drug Administration and European Commission for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis
SAN DIEGO--(BUSINESS WIRE)--Endeavor BioMedicines ('Endeavor'), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced that both the European Commission (EC) and the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to its investigational therapy, taladegib (ENV-101), for the treatment of idiopathic pulmonary fibrosis (IPF). Endeavor is currently enrolling patients in the Phase 2b WHISTLE-PF (Wound-remodeling Hedgehog-Inhibitor ILD Study Testing Lung Function Endpoints-PF) clinical trial of taladegib in IPF, a chronic, progressive lung disease with limited treatment options. Enrollment in the WHISTLE-PF trial is on track and expected to be completed in 2026. 'Receiving Orphan Drug Designation for taladegib in both the United States and European Union underscores the significant unmet medical need for patients with IPF,' said Lisa Lancaster, M.D., Chief Medical Officer, Endeavor BioMedicines. 'We are encouraged by the potential of taladegib to reverse the course of disease across multiple measures of IPF, which is a major step forward from current standard-of-care. I am very proud of our team, which is executing the Phase 2b WHISTLE-PF trial with a remarkable sense of purpose, driven by our mission to push the boundaries of what is possible and restore hope to patients and their families.' Orphan Drug Designation in the European Union (EU) is granted by the EC based on a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products. It is intended to encourage the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases with a prevalence of not more than five in 10,000 in the EU. The designation provides special incentives for sponsors, including eligibility for protocol assistance and exemptions or reductions in certain regulatory fees, as well as 10 years of marketing exclusivity if the product is approved for the designated use. The FDA grants Orphan Drug Designation to drugs and biologics intended for the treatment, diagnosis or prevention of rare diseases or conditions affecting fewer than 200,000 people in the U.S. Orphan Drug Designation provides sponsors certain benefits, including financial incentives to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for that use. About the WHISTLE-PF Trial The Phase 2b WHISTLE-PF clinical trial is a global, randomized, placebo-controlled study evaluating the therapeutic potential of taladegib in individuals with IPF (NCT06422884). The WHISTLE-PF trial will evaluate the efficacy of a range of taladegib doses through 24 weeks of treatment, characterize the investigational compound's safety and tolerability, assess its effect on patient reported outcomes and its effects on lung function, lung capacity and lung fibrosis as measured by chest high-resolution computed tomography. About Taladegib Endeavor's investigational drug taladegib is a Hedgehog (Hh) signaling pathway inhibitor. By binding to and inhibiting a key receptor in the Hh pathway, taladegib stops the abnormal accumulation of myofibroblasts that cause fibrosis. This may resolve the excessive wound-healing process seen in pulmonary fibrosis, improving lung volume and function. About Idiopathic Pulmonary Fibrosis IPF is a chronic, progressive lung disease that affects more than 150,000 adults in the United States. Although the exact cause of IPF is unknown, various environmental factors can deliver repeated injuries to lung cells that trigger abnormal wound-healing processes and life-threatening lung scarring. IPF is a chronic disease with limited treatment options and a very poor prognosis. The average life expectancy is three to five years after diagnosis. About Endeavor BioMedicines Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor's lead candidate, taladegib (ENV-101), is an inhibitor of the Hedgehog signaling pathway in development for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). More information is available at and on LinkedIn or X.
